Trevi Therapeutics, Inc. (TRVI)
13.82
+0.30
(+2.18%)
USD |
NASDAQ |
Oct 29, 16:00
13.82
0.00 (0.00%)
After-Hours: 20:00
Trevi Therapeutics Enterprise Value : 1.607B for Oct. 28, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 28, 2026 | 1.607B |
| October 27, 2026 | 1.583B |
| October 26, 2026 | 1.463B |
| October 23, 2026 | 1.478B |
| October 22, 2026 | 1.525B |
| October 21, 2026 | 1.500B |
| October 20, 2026 | 1.509B |
| October 19, 2026 | 1.377B |
| October 16, 2026 | 1.374B |
| October 15, 2026 | 1.406B |
| October 14, 2026 | 1.399B |
| October 13, 2026 | 1.432B |
| October 12, 2026 | 1.523B |
| October 09, 2026 | 1.560B |
| October 08, 2026 | 1.508B |
| October 07, 2026 | 1.553B |
| October 06, 2026 | 1.559B |
| October 05, 2026 | 1.636B |
| October 02, 2026 | 1.663B |
| October 01, 2026 | 1.701B |
| September 30, 2026 | 1.721B |
| September 29, 2026 | 1.735B |
| September 28, 2026 | 1.733B |
| September 25, 2026 | 1.734B |
| September 24, 2026 | 1.772B |
| Date | Value |
|---|---|
| September 23, 2026 | 1.741B |
| September 22, 2026 | 1.852B |
| September 21, 2026 | 1.802B |
| September 18, 2026 | 1.811B |
| September 17, 2026 | 1.848B |
| September 16, 2026 | 1.819B |
| September 15, 2026 | 1.824B |
| September 14, 2026 | 1.945B |
| September 11, 2026 | 1.946B |
| September 10, 2026 | 1.948B |
| September 09, 2026 | 2.052B |
| September 08, 2026 | 2.077B |
| September 04, 2026 | 2.140B |
| September 03, 2026 | 2.111B |
| September 02, 2026 | 2.110B |
| September 01, 2026 | 2.042B |
| August 31, 2026 | 2.046B |
| August 28, 2026 | 2.073B |
| August 27, 2026 | 2.240B |
| August 26, 2026 | 2.234B |
| August 25, 2026 | 2.238B |
| August 24, 2026 | 2.257B |
| August 21, 2026 | 2.240B |
| August 20, 2026 | 2.281B |
| August 19, 2026 | 2.361B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals, Inc. | 1.882B |
| Corcept Therapeutics, Inc. | 9.013B |
| Veru, Inc. | 15.60M |
| Johnson & Johnson | 679.85B |
| Eli Lilly & Co. | 1.259T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -17.80M |
| Total Expenses (Quarterly) | 17.80M |
| EPS Diluted (Quarterly) | -0.1136 |
| Earnings Yield | -2.48% |
| Normalized Earnings Yield | -2.481 |